Murat Yildirim

6PUBLICATIONS
22CO-AUTHORS
Personality and individual differencesOther European languagesToxicology (incl. clinical toxicology)Instrumental methods (excl. immunological and bioassay methods)Pharmaceutical delivery technologies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Aug 27, 2025
Brexpiprazole for anxiety symptoms in schizophrenia: a pooled analysis of short- and long-term trials.

Zahinoor Ismail, Shivani Kapadia, Anton M Palma

|May 05, 2025
Exploring Patient, Caregiver, and Prescriber Preferences for an Injectable Antipsychotic Administered Every 2 Months for the Maintenance Treatment of Schizophrenia: A Multicenter Qualitative Interview Study Conducted in Europe.

Sofia Pappa, Murat Yildirim, Stephanie Loomer

|Mar 02, 2025
Survey on the Initiation of Aripiprazole Once-Monthly via a Two-Injection Start in Adult Patients with Schizophrenia: Experience of European Healthcare Professionals.

Andrea Fagiolini, Karolina Leopold, Sofia Pappa

|Jun 14, 2023
Aripiprazole Plasma Concentrations Delivered from Two 2-Month Long-Acting Injectable Formulations: An Indirect Comparison.

Matthew Harlin, Craig Chepke, Frank Larsen

|Jun 05, 2023
Safety and efficacy of aripiprazole 2-month ready-to-use 960 mg: secondary analysis of outcomes in adult patients with bipolar I disorder in a randomized, open-label, parallel-arm, pivotal study.

Roger S McIntyre, Pedro Such, Murat Yildirim

|Mar 24, 2023
A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder.

Matthew Harlin, Murat Yildirim, Pedro Such

Pageof 1

Frequent Collaborators

3 joint publications

Matthew Harlin

3 joint publications

Pedro Such

3 joint publications

Jessica Madera-McDonough

3 joint publications

Frank Larsen